Recommendations for European Medicines Agency communication on medicines; 40 years of PIC/S

1 June 2011

A report written by an independent expert has highlighted a number of recommendations to help improve the European Medicines Agency's communication on the benefits and risks of medicines.

The report represents the outcome of a year-long project carried out by Frederic Bouder on the invitation of the Agency. The project aimed to provide evidence-based input to help improve the EMA's communication activities on medicines. This is one of the commitments described in the Agency's Road Map to 2015 (The Pharma Letter January 27).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical